SCHEMBL614250

SCHEMBL614250

CC1(C)CC(c2ccc(O)cc2O)CC(C)(C)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
AGTR1 P30556 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TYR P14679 2/20 0.41
HSP90AA1 P07900 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11036106 0.79 NPC1 (0.40) NPC1MAPTKDM4EUSP2ALDH1A1
SCHEMBL19249421 0.73 TYR (0.48) MAPTALDH1A1GAAHPGDALOX12
SCHEMBL6433472 0.72 ESR2 (0.59) NPC1MAPTKDM4EUSP2ALDH1A1
SCHEMBL6433469 0.72 ESR2 (0.59) NPC1MAPTKDM4EUSP2ALDH1A1
SCHEMBL6437628 0.71 TRPA1 (0.53) NPC1MAPTKDM4EUSP2ALDH1A1
SCHEMBL613627 0.70 TYR (0.40) NPC1MAPTKDM4EUSP2ALDH1A1
SCHEMBL613628 0.70 TYR (0.40) NPC1MAPTKDM4EUSP2ALDH1A1
SCHEMBL29871375 0.70 ALDH1A1 (0.43) MAPTALDH1A1GAAHPGDALOX12
SCHEMBL3162433 0.70 ALDH1A1 (0.43) MAPTALDH1A1GAAHPGDALOX12
SCHEMBL11467079 0.69 CHRNB2 (0.42) NPC1MAPTKDM4EUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016102399-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102398-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102402-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102400-A1 COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT L'OREAL (FR) 2016-06-30 WO claimed
EP-2529735-B1 COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY GALDERMA RES & DEV (FR) 2014-06-25 EP claimed
US-8372879-B2 4-(heterocycloalkyl) benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-12 US claimed
EP-2529735-A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics Galderma Research & Development (FR) 2012-12-05 EP claimed
EP-2373310-B1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RES & DEV (FR) 2012-10-10 EP claimed
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-16 US claimed
EP-2373310-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS Galderma Research & Development (FR) 2011-10-12 EP claimed
WO-2010063773-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 WO claimed
WO-2016102398-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102402-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102400-A1 COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102399-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE L'OREAL (FR) 2016-06-30 WO disclosed
EP-2529735-A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics Galderma Research & Development (FR) 2012-12-05 EP disclosed
EP-2373310-B1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RES & DEV (FR) 2012-10-10 EP disclosed
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-16 US disclosed
EP-2373310-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS Galderma Research & Development (FR) 2011-10-12 EP disclosed
WO-2010063773-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS TYR, DDT, PAH NPC1 2723/4885MAPT 2448/4885KDM4E 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.